Biohit Oyj Press Release December 12, 2014 at 4:00 pm. local time (EET)
Biohit Oyj and Doctagon have agreed to co-operate thereby Doctagon will offer diagnostic tests by Biohit to its customers. Co-operation covers Biohit’s tests for diagnosis of digestinal diseases. Based on the test results, Doctagon medical services offer customers tailor-made follow-up services.
GastroPanel is a non-invasive gastric health test which reveals whether the gastric mucosa is healthy or not. The test diagnoses H. pylori infection and atrophic gastritis, caused by H. pylori of autoimmune disease. These results can be used to assess whether patients have risk of gastric or esophagus cancer, peptic ulcer disease or risk of vitamin B12, calcium or iron deficiency and what further examinations and treatment is needed (attachment: additional information).
Active vitamin B12 test allows the diagnosis of B12 vitamin deficiency from blood sample. Vitamin B12 deficiency can occur in seemingly healthy people, and the risk increases with age. The test does not measure the level of total B12, but it measures the available active form of vitamin B12, holotranscobalamin, level in the blood.
ColonView is a diagnostic quick test for early detection, screening and diagnostics of the risk of colorectal cancer (colon cancer). This sensitive test detects fecal occult blood derived from both the upper and lower gastrointestinal tract - with improved sensitivity for even small benign lesions (polyps) and cancer precursors (adenomas).
Calprotectin test enables the differentiation of inflammatory bowel disease IBD and irritable bowel syndrome (IBS) as well as monitoring of inflammatory bowel disease.
Celiac Quick test measures gluten antibodies in serum and negative results exclude celiac disease. The test will bring clear benefits in healthcare costs, because it reduces the number of unnecessary endoscopies.
CEO Stefan Wentjärvi, Doctagon: ’We see two Finnish innovators in this co-operation. Our own expertise is proactive treatment because we want to tackle problems when they are still small. Diagnosis of gastric diseases is suitable for our preventive activities.’
CEO Semi Korpela, Biohit Oyj: ’Doctagon has an innovative grip to Finnish health care and medical service co-operation enables direct treatment support to Biohit's laboratory services customers.’
Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com
Attachment: additional information
Biohit in brief
Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com
Doctagon in brief
Doctagon is a Finnish pioneer of healthcare services. We employ 150 professionals and our annual turnover is 13 million euros. Doctagon has successfully renewed medical services for the elderly in over 30 municipalities and been a pioneer in house call services. Doctagon’s medical centre is located in the heart of Helsinki and serves both private and occupational health care customers. www.doctagon.fi/en
